Vanflyta (quizartinib) has won US approval alongside standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherap 21 July 2023
ADC Therapeutics has announced a pause in patient enrollment in the Phase II LOTIS-9 trial of Zynlonta (loncastuximab tesirine-lpyl) and rituximab (Lonca-R) in 12 July 2023
US biotech BioMarin Pharmaceutical has won US approval for Roctavian (valoctocogene roxaparvovec-rvox) gene therapy for the treatment of severe hemophilia A wit 30 June 2023
Dublin-headquartered protein specialist Prothena has published results from the Phase III VITAL trial in a journal of the American Society of Hematology (ASH). 30 June 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.